A study on the urinary and fecal excretion of furazolidone in rats by means of mutagenicity assays.
The urinary and fecal excretion of furazolidone in rats was studied by means of mutagenicity assays: when animals received a single dose by gavage (1 to 10 mg/100 g body wt) the mutagenic activity recovered in urines accounted for less than 0.1% of the administered dose and quickly disappeared. After prolonged (1 week) treatments, however, some mutagenicity was retained in urine concentrates until the fifth to seventh days. Similarly the fecal excretion of mutagenicity accounted for less than 0.1% of the administered dose and disappeared within the third day. The efficient deactivation of furazolidone observed in vivo was shown to be unaffected by the amount of gut bacteria in treated animals; in in vitro experiments it turned out to be actively performed by a rat intestine homogenate fraction, working more efficiently under hypoxic conditions.
D000818:Animals; D001711:Biotransformation; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000032:analysis; D005664:Furazolidone / Q000378:metabolism* / Q000633:toxicity; D008297:Male; D009152:Mutagenicity Tests; D051381:Rats; D011919:Rats, Inbred Strains
D005664:Furazolidone